IMEMR
EMRO
Volume 6, Issue 4 (2025)
J Clinic Care Skill 2025, 6(4): 219-223 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2025/08/19 | Accepted: 2025/09/29 | Published: 2025/10/6
Received: 2025/08/19 | Accepted: 2025/09/29 | Published: 2025/10/6
How to cite this article
Rad F, Hadinia A, Masoudifar S. Red Blood Cell Alloimmunization in Thalassemia Patients in South-West Iran. J Clinic Care Skill 2025; 6 (4) :219-223
URL: http://jccs.yums.ac.ir/article-1-428-en.html
URL: http://jccs.yums.ac.ir/article-1-428-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
2- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
Abstract (371 Views)
Aims: Despite numerous studies on the prevalence of alloimmunization, its exact rate remains uncertain in many populations. In light of the Iranian Blood Transfusion Organization’s recent national program to reduce alloantibody formation, this study investigated the prevalence of alloimmunization among thalassemia patients in Kohgiluyeh and Boyer-Ahmad Province, Iran, and explored associated factors, such as donor-recipient antigen homogeneity and early transfusion initiation.
Instrument & Methods: This cross-sectional study was conducted on 134 beta-thalassemia major patients registered at Shahid Beheshti Hospital, Yasuj, Iran. Antibody screening was performed using both the standard tube method and the gel method in the immunohematology laboratory of Yasuj University of Medical Sciences.
Findings: Out of 134 cases, 73 (54.48%) were female and 61 (45.52%) were male, with a mean age of 19.51±8.50 years. A high donor-recipient antigen homogeneity is suggested by the fact that 132 (98.5%) patients were native to Yasuj. All patients received ABO and Rh (D)-matched, leukodepleted blood transfusions at intervals ranging from 14 to 60 days (mean: 22.7±6.3 days); 65.7% were splenectomized. Alloantibodies were detected in two patients (1.49% prevalence; one with anti-K and one with anti-C), both of whom had undergone splenectomy. No autoantibodies or positive direct antiglobulin test results were observed.
Conclusion: There is a low prevalence of RBC alloimmunization among BTM patients in Kohgiluyeh and Boyer-Ahmad Province.
Instrument & Methods: This cross-sectional study was conducted on 134 beta-thalassemia major patients registered at Shahid Beheshti Hospital, Yasuj, Iran. Antibody screening was performed using both the standard tube method and the gel method in the immunohematology laboratory of Yasuj University of Medical Sciences.
Findings: Out of 134 cases, 73 (54.48%) were female and 61 (45.52%) were male, with a mean age of 19.51±8.50 years. A high donor-recipient antigen homogeneity is suggested by the fact that 132 (98.5%) patients were native to Yasuj. All patients received ABO and Rh (D)-matched, leukodepleted blood transfusions at intervals ranging from 14 to 60 days (mean: 22.7±6.3 days); 65.7% were splenectomized. Alloantibodies were detected in two patients (1.49% prevalence; one with anti-K and one with anti-C), both of whom had undergone splenectomy. No autoantibodies or positive direct antiglobulin test results were observed.
Conclusion: There is a low prevalence of RBC alloimmunization among BTM patients in Kohgiluyeh and Boyer-Ahmad Province.
Keywords:
References
1. Cooley TB, Witwer ER, Lee P. Anemia in children: With splenomegaly and peculiar changes in the bones report of cases. Am J Dis Child. 1927;34(3):347-63. [Link] [DOI:10.1001/archpedi.1927.04130210022002]
2. De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, et al. β-thalassemia distribution in the old world: An ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis. 2017;9(1):e2017018. [Link] [DOI:10.4084/mjhid.2017.018]
3. Thein SL. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells Mol Dis. 2018;70:54-65. [Link] [DOI:10.1016/j.bcmd.2017.06.001]
4. Abu-Shaheen A, Heena H, Nofal A, Abdelmoety DA, Almatary A, Alsheef M, et al. Epidemiology of thalassemia in Gulf Cooperation Council countries: A systematic review. Biomed Res Int. 2020;2020(1):1509501. [Link] [DOI:10.1155/2020/1509501]
5. Rezabeigi Davarani E, Mohseni Takaloo F, Vahidnia A, Daneshi S, Rezabeigi Davarani M, Khanjani N, et al. Epidemiological investigation of a twenty-year major β-thalassemia surveillance in Kerman, Iran. Arch Hyg Sci. 2020;9(4):265-74. [Link] [DOI:10.52547/ArchHygSci.9.4.265]
6. Joola P, Andashti B, Hosseini SA, Zadeh SMM, Bahrami N. The frequency of beta-thalassemia mutations among carriers in Dezful city, southwest Iran. Iran J Public Health. 2020;49(12):2438. [Link] [DOI:10.18502/ijph.v49i12.4839]
7. Rund D. Thalassemia 2016: Modern medicine battles an ancient disease. Am J Hematol. 2016;91(1):15-21. [Link] [DOI:10.1002/ajh.24231]
8. Forni GL, Grazzini G, Boudreaux J, Agostini V, Omert L. Global burden and unmet needs in the treatment of transfusion-dependent β-thalassemia. Front Hematol. 2023;2:1187681. [Link] [DOI:10.3389/frhem.2023.1187681]
9. Tanhehco YC, Berns JS. Red blood cell transfusion risks in patients with end‐stage renal disease. Semin Dial. 2012;25(5):539-44. [Link] [DOI:10.1111/j.1525-139X.2012.01089.x]
10. Jawish TAA, Hessen HM, Alshafeea MA, Mohamedahmed KA, Ahmed EA, Modawe GA, et al. Red cell alloimmunization in repeatedly transfused sudanese patients with leukemia in Northern Sudan. Asian Pac J Cancer Prev. 2023;24(1):21-4. [Link] [DOI:10.31557/APJCP.2023.24.1.21]
11. Cohn CS, Delaney M, Johnson S, Katz LM, Schwartz J. Technical manual. Bethesda: Amer Assn of Blood Banks; 2023. [Link]
12. Darvishi P, Azami M, Sayehmiri K, Sayehmiri F, Goodarzi A, Azarkeivan A, et al. Red blood cell alloimmunization in Iranian beta‐thalassemia patients: A systematic review and meta‐analysis. ISBT Sci Ser. 2016;11(3):163-73. [Link] [DOI:10.1111/voxs.12299]
13. Kiani A, Abdi J, Shirkhani Y, Kashi M. Prevalence of alloimmunization against RBC antigens in thalassemia major patients of Lorestan province in 1383. J Iran Blood Transfus. 2006;3(3):265-71. [Persian] [Link]
14. Karimi M, Nikrooz P, Kashef S, Jamalian N, Davatolhagh Z. RBC alloimmunization in blood transfusion‐dependent β‐thalassemia patients in southern Iran. Int J Lab Hematol. 2007;29(5):321-6. [Link] [DOI:10.1111/j.1365-2257.2006.00856.x]
15. Kosaryan M, Mahdavi MR, Roshan P, Hojjati MT. Prevalence of alloimmunisation in patients with beta thalassaemia major. Blood Transfus. 2012;10(3):396-7. [Link]
16. Hiradfar AA, Keikhai B, Pedram M. Determination of clinical prevalence and predominant pattern of RBCs alloimmunization among transfusion dependent thalassemic patients in Ahvaz. Jundishapur Sci Med J. 2010;9(5):441. [Persian] [Link]
17. Vaziri M, JavadzadehShahshahani H, Moghaddam M, Taghvaee N. Prevalence and specificities of red cell alloantibodies in transfusion-dependent beta thalassemia patients in Yazd. Iran J Pediatr Hematol Oncol. 2015;5(2):93-9. [Link]
18. Meshi AA, Abu-Tawil H, Hamzi AA, Madkhali BA, Maghfori AB, Alnami II, et al. Red cell alloimmunisation among sickle cell disease and thalassemia patients following rh-and k-matched red cell transfusion in Southwestern Saudi Arabia: A multicenter study. Int J Gen Med. 2024;17:2855-64. [Link] [DOI:10.2147/IJGM.S444949]
19. Bakhshandeh Z, Amirizadeh N, Maghsoodlu M, Oodi A, Naghi A, Khazaeli AA, et al. Developing a databank for multiple transfusion patients: Rh antigen and phenotype distribution among 3000 regular blood donors in Iran. Transfus Apher Sci. 2021;60(3):103124. [Link] [DOI:10.1016/j.transci.2021.103124]
20. Indriani V, Mulyono B, Triyono T, Handayaningsih AE, Chandra LA. Prevalence of alloimmunization events in thalassemia patients with repeated transfusions in the rhesus blood group system: A systematic review and meta analysis. J Clin Med Res. 2025;17(2):106-18. [Link] [DOI:10.14740/jocmr6142]
21. Prigent A, Maillard N, Absi L, Aloui C, Cognasse F, Laradi S, et al. From donor to recipient: Current questions relating to humoral alloimmunization. Antibodies. 2014;3(1):130-52. [Link] [DOI:10.3390/antib3010130]
22. Evers D, Van Der Bom JG, Tijmensen J, De Haas M, Middelburg RA, De Vooght K, et al. Splenectomy protects humans from red cell alloimmunization. Blood. 2016;128(22):24. [Link] [DOI:10.1182/blood.V128.22.24.24]
23. Hendrickson JE. Red blood cell alloimmunisation: Induction of immunity and potential mitigation strategies. ISBT Sci Ser. 2018;13(1):105-11. [Link] [DOI:10.1111/voxs.12360]
24. Adane T, Enawgaw B. Human leukocyte antigen alloimmunization prevention mechanisms in blood transfusion. Asian J Transfus Sci. 2023;17(2):264-72. [Link] [DOI:10.4103/ajts.ajts_144_21]
25. Garraud O, Chiaroni J. An overview of red blood cell and platelet alloimmunisation in transfusion. Transfus Clin Biol. 2022;29(4):297-306. [Link] [DOI:10.1016/j.tracli.2022.08.140]
26. Rodrigues C, Sell AM, Guelsin GAS, Higa TT, Pagliarini E Silva S, Macedo LC, et al. HLA polymorphisms and risk of red blood cell alloimmunisation in polytransfused patients with sickle cell anaemia. Transfus Med. 2017;27(6):437-43. [Link] [DOI:10.1111/tme.12459]